XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
GOODWILL AND OTHER INTANGIBLE ASSETS
9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2016 were as follows:
 
Specialty
Surgical
Solutions
 
Orthopedics and
Tissue Technologies
 
Total
 
(In thousands)
Goodwill at December 31, 2015
$
284,976

 
$
227,413

 
$
512,389

TEI working capital and purchase price adjustment

 
(174
)
 
(174
)
Foreign currency translation and other
2,203

 
1,218

 
3,421

Balance, September 30, 2016
$
287,179

 
$
228,457

 
$
515,636



The components of the Company’s identifiable intangible assets were as follows:
 
September 30, 2016
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
17 years
 
$
480,614

 
$
(88,567
)
 
$
392,047

Customer relationships
12 years
 
154,222

 
(75,708
)
 
78,514

Trademarks/brand names
30 years
 
91,400

 
(18,704
)
 
72,696

Supplier relationships
27 years
 
34,721

 
(13,307
)
 
21,414

All other (1)
5 years
 
11,134

 
(2,118
)
 
9,016

 
 
 
$
772,091

 
$
(198,404
)
 
$
573,687


 
December 31, 2015
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
17 years
 
$
480,684

 
$
(67,978
)
 
$
412,706

Customer relationships
12 years
 
153,246

 
(68,811
)
 
84,435

Trademarks/brand names
30 years
 
90,837

 
(16,374
)
 
74,463

Supplier relationships
27 years
 
34,721

 
(12,236
)
 
22,485

All other (1)
5 years
 
10,958

 
(1,307
)
 
9,651

 
 
 
$
770,446

 
$
(166,706
)
 
$
603,740

 
(1) 
At September 30, 2016 and December 31, 2015, all other included in-process research and development ("IPR&D") of $1.0 million in both periods, which was indefinite-lived.
Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired in-process research and development) is expected to be approximately $41.5 million in 2016, $40.9 million in 2017, $40.4 million in 2018, $40.4 million in 2019 and $40.2 million in 2020. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.